Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Roche Holding AG (DE:RHO5)
XETRA:RHO5
Holding DE:RHO5?
Track your performance easily
RHO5 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€244.35 - €247.10
Previous Close€245.2
Volume2.84K
Average Volume (3M)2.84K
Market Cap
€220.12B
Enterprise Value€243.30B
Total Cash (Recent Filing)CHF7.51B
Total Debt (Recent Filing)CHF25.39B
Price to Earnings (P/E)17.7
BetaN/A
Next Earnings
Jan 30, 2025EPS Estimate
€8.96Last Dividend Ex-Date
Mar 14, 2024Dividend Yield3.75%
Share Statistics
EPS (TTM)13.88
Shares Outstanding800,578,845
10 Day Avg. Volume0
30 Day Avg. Volume2,836
Standard Deviation0.05
R-Squared0.04
Alpha0.00155
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)3.40
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€305.61Price Target Upside24.64% Upside
Rating ConsensusHold
Number of Analyst Covering13
Roche Holding AG News
Bulls Say, Bears Say
Bulls Say
Clinical ReadoutsRoche will deliver a substantial number of clinical readouts, which can decide a turnaround to the story.
Growth MomentumRoche's strong high-single-digit growth momentum is expected to persist, supported by an updated chart suggesting undervaluation of its pipeline.
Sales And PerformanceThree potential assets are forecasted to generate over $5bn in sales, with Giredestrant for breast cancer showing the highest conviction.
Bears Say
Analyst RatingMaintain Underweight rating ahead of the CT-388/CT-996 data to be presented at the EASD meeting.
Competitive AdvantageData have not shown a clear benefit versus competition, and safety does not seem to provide any advantage.
Research And DevelopmentR&D needs to deliver to make the investment case really attractive.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
10.23% Mutual Funds
0.04% Other Institutional Investors
80.25% Public Companies and
Individual Investors
RHO5 FAQ
What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest stock price was €244.35 and its highest was €247.10 in the past 12 months.
What is Roche Holding AG’s market cap?
Currently, no data Available
When is Roche Holding AG’s upcoming earnings report date?
Roche Holding AG’s upcoming earnings report date is Jan 30, 2025 which is in 69 days.
How were Roche Holding AG’s earnings last quarter?
Roche Holding AG released its earnings results on Jul 25, 2024. The company reported €10.922 earnings per share for the quarter, beating the consensus estimate of €9.999 by €0.924.
Is Roche Holding AG overvalued?
According to Wall Street analysts Roche Holding AG’s price is currently Undervalued.
Does Roche Holding AG pay dividends?
Roche Holding AG pays a Annually dividend of €10.25 which represents an annual dividend yield of 3.75%. See more information on Roche Holding AG dividends here
What is Roche Holding AG’s EPS estimate?
Roche Holding AG’s EPS estimate is €8.96.
How many shares outstanding does Roche Holding AG have?
Roche Holding AG has 702,562,700 shares outstanding.
What happened to Roche Holding AG’s price movement after its last earnings report?
Roche Holding AG reported an EPS of €10.922 in its last earnings report, beating expectations of €9.999. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Roche Holding AG?
Currently, no hedge funds are holding shares in DE:RHO5
---
Roche Holding AG Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.89%
12-Months-Change
Fundamentals
Return on Equity
38.68%
Trailing 12-Months
Asset Growth
13.03%
Trailing 12-Months
Company Description
Roche Holding AG
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
---
RHO5 Company Deck
---
RHO5 Earnings Call
Q2 2024
0:00 / 0:00
---
RHO5 Stock 12 Month Forecast
Average Price Target
€305.61
▲(24.64% Upside)
Technical Analysis
Best Analysts Covering RHO5
1 Year
1 Year Success Rate
28/42 ratings generated profit
1 Year Average Return
+6.27%
reiterated a sell rating last month
Copying Richard Vosser's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +6.27% per trade.
---